229 related articles for article (PubMed ID: 34272305)
1. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
3. Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.
Han X; Lu H; Tang X; Zhao Y; Liu H
Immun Inflamm Dis; 2022 Jan; 10(1):43-59. PubMed ID: 34582114
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
5. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
6. Model for predicting prognosis and immunotherapy based on CD
Bao W; Song Z; Wan H; Yu X; Chen Z; Jiang Y; Chen X; Le K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9839-9855. PubMed ID: 37248319
[TBL] [Abstract][Full Text] [Related]
7. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind A; Gisselsson D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1397. PubMed ID: 33932141
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham M; Lucas PC; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
bioRxiv; 2023 Aug; ():. PubMed ID: 37662409
[TBL] [Abstract][Full Text] [Related]
10. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Trujillo JA; Sweis RF; Bao R; Luke JJ
Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
Kanemura H; Hayashi H; Tomida S; Tanizaki J; Suzuki S; Kawanaka Y; Tsuya A; Fukuda Y; Kaneda H; Kudo K; Takahama T; Imai R; Haratani K; Chiba Y; Otani T; Ito A; Sakai K; Nishio K; Nakagawa K
JTO Clin Res Rep; 2022 Aug; 3(8):100373. PubMed ID: 35941997
[TBL] [Abstract][Full Text] [Related]
12. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
[TBL] [Abstract][Full Text] [Related]
13. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
14. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
15. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
17. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas.
Song M; Sun Y; Hu Y; Wang C; Jin Y; Liu Y; Da Y; Zhao Q; Zheng R; Li L
Int Immunopharmacol; 2024 May; 133():112145. PubMed ID: 38691920
[TBL] [Abstract][Full Text] [Related]
19. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
20. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
